Antitumor agent-122
Antitumor agent-122 is a potent multi-target antitumor agent that exerts its effects through the induction of ferroptosis, autophagy, apoptosis, and cell cycle arrest. In the ferroptosis pathway, Antitumor agent-122 inhibits GPX4 expression and upregulates FACL4 expression, increasing intracellular lipid peroxidation and ferrous ion levels. In the autophagy pathway, Antitumor agent-122 induces autophagy by inhibiting the AKT/mTOR signaling pathway. In the apoptosis and cell cycle pathways, Antitumor agent-122 arrests cells at the G1/S phase and subsequently promots mitochondrial pathway-mediated apoptosis. Antitumor agent-122 can be used in the research of solid tumors including gastric, liver, ovarian, and bladder cancers.
For research use only. We do not sell to patients.
- CAS No.: 2378641-43-9
- Formula: C28H30N4O2S2
- Molecular Weight:518.69
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
GPX4 |
ACSL4 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
3.6 μM
Compound: 5j
|
Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
|
[PMID: 37972528] |
| HK-2 | IC50 |
14.92 μM
Compound: 5j
|
Antiproliferative activity against human HK-2 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human HK-2 cells incubated for 48 hrs by MTT assay
|
[PMID: 37972528] |
| HUVEC | IC50 |
16.74 μM
Compound: 5j
|
Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay
Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay
|
[PMID: 37972528] |
| MGC-803 | IC50 |
5.23 μM
Compound: 5j
|
Antiproliferative activity against human MGC-803 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human MGC-803 cells incubated for 48 hrs by MTT assay
|
[PMID: 37972528] |
| SK-OV-3 | IC50 |
1.43 μM
Compound: 5j
|
Antiproliferative activity against human SK-OV-3 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human SK-OV-3 cells incubated for 48 hrs by MTT assay
|
[PMID: 37972528] |
| T-24 | IC50 |
3.03 μM
Compound: 5j
|
Antiproliferative activity against human T24 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human T24 cells incubated for 48 hrs by MTT assay
|
[PMID: 37972528] |
In Vitro
Antitumor agent-122 (compound 5j) inhibits the proliferation of MGC-803, HepG-2, SKOV-3, and T24 cells, with IC50 values of 5.23, 3.60, 1.43, and 3.03 μM, respectively[1].
Antitumor agent-122 exhibits low cytotoxicity in HK2 and HUVEC cells, with IC50 values of 14.92 and 16.74 μM, respectively[1].
Antitumor agent-122 inhibits the proliferation of cisplatin-resistant A549/DDP cells[1].
Antitumor agent-122 (5 μM; 24 h) induces ferroptosis in T24 cells by downregulating GPX4 expression, upregulating ACSL4 expression, and promoting the accumulation of lipid peroxides, ferrous ions, superoxide anions, and ROS[1].
Antitumor agent-122 (5 μM; 24 h and 48 h) induces ferroptosis-like mitochondrial morphological changes and autophagosome formation in T24 cells[1].
Antitumor agent-122 (2, 5, 8 μM; 24 h) induces autophagy in T24 cells by upregulating LC3B, downregulating P62, inhibiting AKT/mTOR-related signaling, and activating ERK signaling[1].
Antitumor agent-122 (1–5 μM; 7 days) reduces colony formation in T24 cells[1].
Antitumor agent-122 (1–10 μM; 0, 24, 48 h) inhibits T24 cell migration, and its anti-migratory effect is attenuated by the ERK inhibitor FR180204 (HY-12275)[1].
Antitumor agent-122 (2, 5, 8 μM; 24 h) promotes mitochondrial pathway-mediated apoptosis in T24 cells by upregulating the expression of cleaved-caspase 3, cleaved-PARP, Bax, Bak, and Bad[1].
Antitumor agent-122 (2, 5, and 8 μM; 24 h) upregulates p21 and downregulates MCM5 in T24 cells, inducing G1/S phase cell cycle arrest[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:T24
-
Concentration:5 μM
-
Incubation Time:24 h
-
Result:Markedly decreased intracellular GPX4 levels and increased FACL4 expression.
-
Cell Line:T24
-
Concentration:2, 5, 8 μM
-
Incubation Time:24 h
-
Result:Upregulated LC3B and decreased P62, confirming autophagy induction. Decreased phosphorylated AKT1, AKT1 and mTOR expression, and induced ERK1/2 phosphorylation in a dose-dependent manner.
Upregulated cleaved-caspase 3, cleaved-PARP, Bax, Bak and Bad.
-
Cell Line:T24
-
Concentration:1, 2, 3, 4, 5 μM
-
Incubation Time:7 days
-
Result:Reduced colony formation at different concentrations.
-
Cell Line:T24
-
Concentration:1, 5, 7, 10 μM; FR180204 at 1, 2, 3 μM
-
Incubation Time:0, 24, 48 h
-
Result:Inhibited T24 cell migration in a time- and concentration-dependent manner. Co-incubation with ERK inhibitor FR180204 (HY-12275) reduced the antimigratory effect.
-
Cell Line:T24
-
Concentration:2, 5, 8 μM
-
Incubation Time:24 h
-
Result:Induced G1/S cell cycle arrest in a concentration-dependent manner. The result was consistent with omics analysis and indicated cell cycle blockade after treatment.
Upregulated p21 and downregulated MCM5.
In Vivo
Antitumor agent-122 (5, 15 mg/kg; intraperitoneal injection; once every two days; for 21 days) has antitumor activity with limited toxicity in HepG-2 xenograft nude mouse model[1].
Antitumor agent-122 (5, 15 mg/kg; i.p.; once every two days; for 21 days) exhibits antitumor activity in SKOV-3 xenograft nude mouse model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:T24 xenograft nude mouse model[1]
-
Dosage:5, 15 mg/kg
-
Administration:Intraperitoneal injection (i.p.); once every two days; for 21 days
-
Result:Suppressed T24 xenograft tumor growth. At 15 mg/kg, achieved a tumor inhibition ratio (TIR) of 56.3%, exceeding the effective antitumor threshold of 40%.
Showed lower antitumor activity in the low-dose group than in the high-dose group, indicating a dose-dependent effect.
Did not cause obvious severe body weight loss during treatment, suggesting acceptable tolerability.
-
Animal Model:HepG-2 xenograft nude mouse model[1]
-
Dosage:5, 15 mg/kg
-
Administration:Intraperitoneal injection (i.p.); once every two days; for 21 days
-
Result:Suppressed HepG-2 xenograft tumor growth. At 15 mg/kg, achieved a TIR of 50.0%, indicating effective in vivo antitumor activity.
Showed lower antitumor activity in the low-dose group than in the high-dose group.
Reduced tumor volume and tumor weight compared with vehicle group.
Showed less tissue toxicity than amonafide in heart, liver, spleen and lung pathological sections.
-
Animal Model:SKOV-3 xenograft nude mouse model[1]
-
Dosage:5, 15 mg/kg
-
Administration:Intraperitoneal injection (i.p.); once every two days; for 21 days
-
Result:Exhibited antitumor activity in SKOV-3 xenograft model.
Showed significantly less toxicity than amonafide in heart, liver, spleen and lung pathological sections, with the lowest comprehensive toxicity among all tested compounds, and was thus selected for further mechanistic investigation.
Chemical Information
-
CAS No. 2378641-43-9
-
Molecular Weight 518.69
-
Formula C28H30N4O2S2
-
SMILES
S=C(N1CCN(C2=CC=C(C3=C4C=CC=C32)C(N(CCN(C)C)C4=O)=O)CC1)SCC5=CC=CC=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Antitumor agent-122
- 2378641-43-9
- Antitumor agent122
- Antitumor agent 122
- Ferroptosis
- Autophagy
- Apoptosis
- Glutathione Peroxidase
- Akt
- mTOR
- ERK
- ACSL Family
- multi-target antitumor drug
- HepG-2
- SKOV-3
- MGC -803
- T24
- A549/DDP
- T24 xenograft
- HepG-2 xenograft
- SKOV-3 xenograft
- gastric cancer
- hepatocellular carcinoma
- ovarian cancer
- bladder cancer
- Inhibitor
- inhibitor
- inhibit